应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BL Blackline Inc.
已收盘 07-02 16:00:00 EDT
29.88
+0.43
+1.46%
盘后
29.83
-0.05
-0.17%
17:19 EDT
最高
30.07
最低
29.18
成交量
105.50万
今开
29.39
昨收
29.45
日振幅
3.04%
总市值
17.53亿
流通市值
13.39亿
总股本
5,866万
成交额
3,137万
换手率
2.35%
流通股本
4,481万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
智通财经网 · 06-08
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
财中社 · 06-04
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
百利天恒：注射用BL-M08D1获临床试验批准
南方财经网 · 06-04
百利天恒：注射用BL-M08D1获临床试验批准
财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观
财报Agent · 04-28
财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观
BlackLine创始人特蕾莎·塔克宣布退出全职高管职务
投资观察 · 03-25
BlackLine创始人特蕾莎·塔克宣布退出全职高管职务
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
智通财经 · 03-22
百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准
Blackline Inc.与Engaged Capital达成合作，任命Storm Duncan和Megan Prichard为董事会成员
美股速递 · 03-10
Blackline Inc.与Engaged Capital达成合作，任命Storm Duncan和Megan Prichard为董事会成员
Blackline与Engaged Capital达成协议，新增两名独立董事强化董事会
美股速递 · 03-10
Blackline与Engaged Capital达成协议，新增两名独立董事强化董事会
百利天恒：自研ADC药物注射用BL-M11D1获批临床
财中社 · 03-04
百利天恒：自研ADC药物注射用BL-M11D1获批临床
Blackline宣布举办伦敦Beyondtheblack峰会，汇聚金融领袖共绘CFO办公室未来蓝图
美股速递 · 03-03
Blackline宣布举办伦敦Beyondtheblack峰会，汇聚金融领袖共绘CFO办公室未来蓝图
Blackline, Inc.盘中异动 股价大跌5.04%
市场透视 · 02-17
Blackline, Inc.盘中异动 股价大跌5.04%
异动解读 | D.A. Davidson下调目标价，Blackline Inc.盘中大跌5.06%
异动解读 · 02-11
异动解读 | D.A. Davidson下调目标价，Blackline Inc.盘中大跌5.06%
Engaged Capital正式提名三位资深独立董事候选人加入Blackline董事会
美股速递 · 02-02
Engaged Capital正式提名三位资深独立董事候选人加入Blackline董事会
Engaged Capital宣布拟向Blackline Inc.董事会提名高素质董事候选人
美股速递 · 01-13
Engaged Capital宣布拟向Blackline Inc.董事会提名高素质董事候选人
Blackline股价盘前上涨1.6% 路透社报道维权投资者拟提名董事推动潜在出售
美股速递 · 01-12
Blackline股价盘前上涨1.6% 路透社报道维权投资者拟提名董事推动潜在出售
【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。
金融界 · 2025-03-02
【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。
百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书
智通财经 · 2025-02-18
百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书
Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%
市场透视 · 2025-02-16
Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%
Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元
市场透视 · 2025-02-12
Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元
BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿
财报速递 · 2025-02-12
BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿
加载更多
公司概况
公司名称：
Blackline Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
BlackLine, Inc.以BlackLine Systems, Inc之名成立于2001年5月。该公司已经创建了一个全面的基于云计算的软件平台，旨在为所有类型和规模的组织变革和现代化的会计和财务运作。他们的安全可扩展的平台支持关键会计流程，如财务结算，对账，公司间的会计和控制的保证等。通过引入软件来自动化这些流程并使其能够持续运行，他们授权客户提高其财务报告的完整性，提高效率并增强其运营的实时可见性。
发行价格：
--
{"stockData":{"symbol":"BL","market":"US","secType":"STK","nameCN":"Blackline Inc.","latestPrice":29.88,"timestamp":1783022400000,"preClose":29.45,"halted":0,"volume":1054984,"hourTrading":{"tag":"盘后","latestPrice":29.83,"preClose":29.88,"latestTime":"17:19 EDT","volume":23462,"amount":701014.16,"timestamp":1783027199790,"change":-0.05,"changeRate":-0.001673,"amplitude":0.002008},"delay":0,"changeRate":0.014601018675721552,"floatShares":44813100,"shares":58660917,"eps":0.425457,"marketStatus":"已收盘","change":0.43,"latestTime":"07-02 16:00:00 EDT","open":29.39,"high":30.07,"low":29.175,"amount":31373853,"amplitude":0.03039,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.425457,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1477627200000,"exchange":"NASDAQ","adjPreClose":29.45,"preHourTrading":{"tag":"盘前","latestPrice":29.45,"preClose":29.45,"latestTime":"09:20 EDT","volume":805,"amount":23686.58082,"timestamp":1782998410679,"change":0,"changeRate":0,"amplitude":0.013243},"postHourTrading":{"tag":"盘后","latestPrice":29.83,"preClose":29.88,"latestTime":"17:19 EDT","volume":23462,"amount":701014.16,"timestamp":1783027199790,"change":-0.05,"changeRate":-0.001673,"amplitude":0.002008},"volumeRatio":0.782831,"impliedVol":0.7428,"impliedVolPercentile":0.8247},"requestUrl":"/m/hq/s/BL","defaultTab":"news","newsList":[{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BL","BK4134","LABU","BK0239","91194","III","BK4023","688506","02615","LU1815336091.USD","BK4588","BK4585","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","BK0239","91194","BK4134","02615","LU1815336091.USD","BL","688506","BK4023","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154692","title":"百利天恒：注射用BL-M08D1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154692","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640154692?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:54","pubTimestamp":1780570440,"startTime":"0","endTime":"0","summary":"南财智讯6月4日电，百利天恒公告，百利天恒（简称）收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药注射用BL-M08D1（ADC）联合用药的临床试验获得批准，适应症为弥漫大B细胞淋巴瘤。该药物与iza-bren出自同一技术平台，共享同一“连接子+毒素”平台。公司将按规定积极推进研发项目，并及时履行后续信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760550358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0757428866.USD","91194","02615","BK0239","688506","BL","LU1815336091.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167587485","title":"财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1167587485","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167587485?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:31","pubTimestamp":1777357911,"startTime":"0","endTime":"0","summary":"Blackline Inc.将于2026年05月05日盘后披露财报，市场关注订阅收入带动的稳健增长与利润率修复路径。市场一致预期本季度Blackline Inc.收入为1.81亿美元，同比增长8.60%；调整后每股收益为0.45美元，同比增长17.25%；息税前利润为3,433.01万美元，同比增长20.03%。上季度Blackline Inc.实现收入1.83亿美元，同比增长8.10%；毛利率为75.19%；归属于母公司股东的净利润为488.60万美元，净利率2.67%；调整后每股收益为0.63美元，同比增长34.04%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Blackline Inc.本季度营收预计增8.60%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153423500","title":"BlackLine创始人特蕾莎·塔克宣布退出全职高管职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1153423500","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153423500?lang=zh_cn&edition=full","pubTime":"2026-03-25 04:18","pubTimestamp":1774383530,"startTime":"0","endTime":"0","summary":"在创立BlackLine二十五周年之际，公司创始人特蕾莎·塔克正式宣布将于2026年6月2日卸任全职高管职位。作为公司最大个人股东，塔克在卸任后将继续留任董事会成员，并以重要股东身份保持对公司的深度参与。目前全球逾4300家跨行业企业依托BlackLine的协同创新模式与顶尖安全实践，加速数字化转型进程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","BL","BK4023","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621371933?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0757428866.USD","159992","BK0239","LU1815336091.USD","06978","BK4023","BK1161","BK1574","BL","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114322489","title":"Blackline Inc.与Engaged Capital达成合作，任命Storm Duncan和Megan Prichard为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1114322489","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114322489?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:05","pubTimestamp":1773144320,"startTime":"0","endTime":"0","summary":"Blackline Inc.近日宣布，在与活跃投资机构Engaged Capital的协作框架下，正式任命Storm Duncan与Megan Prichard加入公司董事会。这一人事变动旨在进一步强化公司治理结构，并借助新任董事的专业经验推动企业战略发展。此次任命也反映出Blackline积极吸纳多元视角，以应对日益复杂的市场环境。随着两位新成员的加入，Blackline董事会规模得以扩大，治理团队的专业覆盖面进一步拓宽。公司表示，这一举措将有助于提升决策效能，加速全球增长战略的实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL","LU1815336091.USD","LU0757428866.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176931404","title":"Blackline与Engaged Capital达成协议，新增两名独立董事强化董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1176931404","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176931404?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:05","pubTimestamp":1773144300,"startTime":"0","endTime":"0","summary":"Blackline Inc. 已与维权投资机构Engaged Capital达成合作协议，并通过任命两名独立董事进一步优化公司治理结构。此举旨在提升董事会的独立性与专业性，为公司未来发展提供更坚实的决策支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1815336091.USD","BL","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616318725","title":"百利天恒：自研ADC药物注射用BL-M11D1获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318725","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318725?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:46","pubTimestamp":1772621169,"startTime":"0","endTime":"0","summary":"3月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）的药物临床试验获得批准。BL-M11D1是与iza-bren出自同一技术平台、与iza-bren共享同一“连接子+毒素”平台的靶向CD33的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661878918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4231","LU0757428866.USD","BK0239","LU1815336091.USD","ADC","BK4023","BL","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170342507","title":"Blackline宣布举办伦敦Beyondtheblack峰会，汇聚金融领袖共绘CFO办公室未来蓝图","url":"https://stock-news.laohu8.com/highlight/detail?id=1170342507","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170342507?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:00","pubTimestamp":1772528440,"startTime":"0","endTime":"0","summary":"Blackline Inc.近日宣布，将在伦敦举办Beyondtheblack专题活动。此次盛会旨在集结全球金融领域的领军人物，共同探讨和塑造首席财务官（CFO）办公室的未来发展方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4023","LU1815336091.USD","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612446470","title":"Blackline, Inc.盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446470","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612446470?lang=zh_cn&edition=full","pubTime":"2026-02-17 23:21","pubTimestamp":1771341661,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日23时21分，Blackline, Inc.股票出现异动，股价急速下挫5.04%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为1.56%。其相关个股中，The Olb Group, Inc.、Chowchow Cloud International Holdings Limited、Tg-17, Inc.涨幅较大，The Olb Group, Inc.、Freight Technologies, Inc.、Tg-17, Inc.较为活跃，换手率分别为1227.50%、311.22%、196.81%，振幅较大的相关个股有The Olb Group, Inc.、Tg-17, Inc.、Chowchow Cloud International Holdings Limited，振幅分别为76.37%、63.58%、50.96%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217232101a70488d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217232101a70488d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1815336091.USD","BK4023","BL","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188806051","title":"异动解读 | D.A. Davidson下调目标价，Blackline Inc.盘中大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188806051","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188806051?lang=zh_cn&edition=full","pubTime":"2026-02-11 23:02","pubTimestamp":1770822140,"startTime":"0","endTime":"0","summary":"Blackline Inc. (BL) 今日盘中股价大跌5.06%，引起了市场的关注。消息面上，根据路透报道，D.A. Davidson分析师将Blackline Inc.的目标价从56美元下调至45美元。分析师下调目标价通常被视为对公司未来前景的谨慎或负面看法，这可能是导致股价在交易时段内承压下跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113373439","title":"Engaged Capital正式提名三位资深独立董事候选人加入Blackline董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1113373439","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113373439?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:34","pubTimestamp":1770039260,"startTime":"0","endTime":"0","summary":"维权投资机构Engaged Capital今日宣布，已正式向企业软件提供商Blackline Inc.董事会提名三位具备深厚行业背景的独立董事候选人。此次提名旨在强化公司治理结构，为董事会注入新鲜视角与专业经验。Engaged Capital在声明中强调，新董事的加入将有助于提升Blackline的战略决策能力与长期股东价值。Engaged Capital持有Blackline显著股权，持续关注公司治理与业绩表现，此次提名是其积极参与公司战略方向调整的重要举措。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL","LU0757428866.USD","LU1815336091.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160998630","title":"Engaged Capital宣布拟向Blackline Inc.董事会提名高素质董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=1160998630","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160998630?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:05","pubTimestamp":1768305950,"startTime":"0","endTime":"0","summary":"维权投资机构Engaged Capital日前公开表示，计划向金融科技公司Blackline Inc.的董事会推举多名具备卓越资历的独立董事候选人。该举措旨在通过引入新鲜视角，进一步提升公司治理水平与战略决策效能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BL","LU1815336091.USD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126228570","title":"Blackline股价盘前上涨1.6% 路透社报道维权投资者拟提名董事推动潜在出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1126228570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126228570?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:33","pubTimestamp":1768224799,"startTime":"0","endTime":"0","summary":"在路透社披露维权投资者准备提名董事以施压公司考虑出售可能性后，Blackline Inc. (BL) 股价在盘前交易时段上涨1.6%。这一市场反应凸显了投资者对潜在战略变革的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU0757428866.USD","BL","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516364590","title":"【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364590","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516364590?lang=zh_cn&edition=full","pubTime":"2025-03-02 15:34","pubTimestamp":1740900843,"startTime":"0","endTime":"0","summary":"金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1 联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/02153448475153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","09939","III","BK4134","BK1576","159839","BK4023","BK1141","03347","BK1574","LU1815336091.USD","BK0239","BK1161","688506","159938","BK4080","ADC","LU0757428866.USD","BK1583","BL","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512163139","title":"百利天恒(688506.SH)注射用BL-M07D1(HER2-ADC)获II/III期临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512163139","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512163139?lang=zh_cn&edition=full","pubTime":"2025-02-18 17:04","pubTimestamp":1739869479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 公告，公司于近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药注射用BL-M07D1的II/III期临床试验获得批准。据悉，BL-M07D1是一种靶向HER2的创新ADC，具有best-in-class潜力，已在临床试验中展示出显著的抗肿瘤功效。截至本公告披露日，除本次新获得批准的临床试验外，BL-M07D1正于中国及美国的10项I/II/III期临床试验中作为单药或联用进行评估。各项临床研究包括各种HER2表达/突变的实体瘤的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0757428866.USD","III","BK1583","BK0239","BK4023","688506","ADC","BK4080","LU1815336091.USD","BK1576","BK1141","03347","BL","BK4134","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511670288","title":"Blackline, Inc.2024财年实现净利润1.61亿美元，同比增加204.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511670288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511670288?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:00","pubTimestamp":1739635247,"startTime":"0","endTime":"0","summary":"2月16日，Blackline, Inc.公布财报，公告显示公司2024财年净利润为1.61亿美元，同比增加204.75%；其中营业收入为6.53亿美元，同比增加10.68%，每股基本收益为2.59美元。从资产负债表来看，Blackline, Inc.总负债13.42亿美元，其中短期债务3.59百万美元，资产负债比为1.36，流动比率为2.59。机构评级：截至2025年2月16日，当前有10家机构对Blackline, Inc.目标价做出预测，其中目标均价为64.80美元，其中最低目标价为51.00美元，最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000102a24729b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000102a24729b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510034123","title":"Blackline, Inc.股价重挫14.28% 市值跌4.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510034123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510034123?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日22时32分，Blackline, Inc.股票出现波动，股价快速下挫14.28%。截至发稿，该股报54.35美元/股，成交量11.2069万股，换手率0.18%，振幅1.37%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为1.21%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务 形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223202abcc5d49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223202abcc5d49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","LU0757428866.USD","LU1815336091.USD","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135492876","title":"BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1135492876","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135492876?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:12","pubTimestamp":1739308378,"startTime":"0","endTime":"0","summary":"BlackLine 报告的季度每股收益为$0.47，比分析师预期的$0.50低了6%。这比去年同期每股收益$0.69下降了31.88%。公司报告的季度销售额为$1.6946亿，超过了分析师预期的$1.6834亿，高出了0.66%。这比去年同期的$1.5573亿增长了8.82%。以上内容来自Benzinga Earnings专栏，原文如下：BlackLine reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.50 by 6 percent. This is a 31.88 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $169.46 million which beat the analyst consensus estimate of $168","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BlackLine第四季度调整后的每股收益为$0.47，低于预期的$0.50，销售额为$1.6946亿，高于预期的$1.6834亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blackline.com","stockEarnings":[{"period":"1week","weight":0.0895},{"period":"1month","weight":-0.0597},{"period":"3month","weight":-0.1885},{"period":"6month","weight":-0.4524},{"period":"1year","weight":-0.4874},{"period":"ytd","weight":-0.4674}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BlackLine, Inc.以BlackLine Systems, Inc之名成立于2001年5月。该公司已经创建了一个全面的基于云计算的软件平台，旨在为所有类型和规模的组织变革和现代化的会计和财务运作。他们的安全可扩展的平台支持关键会计流程，如财务结算，对账，公司间的会计和控制的保证等。通过引入软件来自动化这些流程并使其能够持续运行，他们授权客户提高其财务报告的完整性，提高效率并增强其运营的实时可见性。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010267},{"month":2,"riseRate":0.4,"avgChangeRate":-0.029288},{"month":3,"riseRate":0.4,"avgChangeRate":-0.032085},{"month":4,"riseRate":0.5,"avgChangeRate":-0.004741},{"month":5,"riseRate":0.6,"avgChangeRate":0.013167},{"month":6,"riseRate":0.8,"avgChangeRate":0.025467},{"month":7,"riseRate":0.5,"avgChangeRate":0.001008},{"month":8,"riseRate":0.666667,"avgChangeRate":0.030293},{"month":9,"riseRate":0.555556,"avgChangeRate":0.013003},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.010357},{"month":11,"riseRate":0.7,"avgChangeRate":0.09203},{"month":12,"riseRate":0.3,"avgChangeRate":-0.011744}],"exchange":"NASDAQ","name":"Blackline Inc.","nameEN":"Blackline Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Blackline Inc.,BL,Blackline Inc.股票,Blackline Inc.股票老虎,Blackline Inc.股票老虎国际,Blackline Inc.行情,Blackline Inc.股票行情,Blackline Inc.股价,Blackline Inc.股市,Blackline Inc.股票价格,Blackline Inc.股票交易,Blackline Inc.股票购买,Blackline Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}